Trial Profile
Improving Public Cancer Care by Implementing Precision Medicine in Norway A Multi-cohort Phase 2 Treatment Clinical Study Investigating Efficacy of Approved Drugs Outside Indication in Patients With Advanced Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2025
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Alpelisib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Bortezomib (Primary) ; Capmatinib (Primary) ; Ceritinib (Primary) ; Cobimetinib (Primary) ; Dabrafenib (Primary) ; Dactinomycin (Primary) ; Dostarlimab (Primary) ; Entrectinib (Primary) ; Fulvestrant (Primary) ; Hydroxycarbamide (Primary) ; Imatinib (Primary) ; Melphalan (Primary) ; Niraparib (Primary) ; Olaparib (Primary) ; Pemigatinib (Primary) ; Pertuzumab/trastuzumab (Primary) ; Pralsetinib (Primary) ; Selpercatinib (Primary) ; Tepotinib (Primary) ; Trametinib (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
- Indications Breast cancer; Cancer; Colorectal cancer; Glioblastoma; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Prostate cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms IMPRESS-N; IMPRESS-Norway
Most Recent Events
- 28 Feb 2024 Number of treatment arms have been increased from 17 to 20 by the addition of 3 new experimental arms of Niraparib, Dostarlimab and Ceritinib.
- 28 Feb 2024 Planned number of patients changed from 2000 to 3000.
- 24 Oct 2023 Preliminary safety analysis of eleven drugs or drug combinations used were presented at the 48th European Society for Medical Oncology Congress.